Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.44 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4652116 | 0.99 | SLC18A3 (0.53) | SLC18A3ALDH1A1ATMKDM4EGAA | |
| SCHEMBL64063 | 0.93 | KDM4E (0.56) | SLC18A3ALDH1A1ATMKDM4EGAA | |
| Iodide SCHEMBL7429946 | 0.87 | OPRL1 (0.41) | SLC18A3ALDH1A1ATMKDM4EGAA | |
| SCHEMBL24244959 | 0.85 | HSD17B10 (0.48) | SLC18A3ALDH1A1ATMKDM4EGAA | |
| SCHEMBL16684739 | 0.83 | HDAC8 (0.61) | ALDH1A1ATMKDM4EGAAHPGD | |
| SCHEMBL1790000 | 0.82 | ALDH1A1 (0.59) | ALDH1A1ATMKDM4EGAAHPGD | |
| SCHEMBL2944396 | 0.82 | ALDH1A1 (0.59) | ALDH1A1ATMKDM4EGAAHPGD | |
| SCHEMBL2949436 | 0.82 | ALDH1A1 (0.59) | ALDH1A1ATMKDM4EGAAHPGD | |
| SCHEMBL27484843 | 0.81 | SLC18A3 (0.63) | SLC18A3ALDH1A1KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL63894 | 0.81 | HDAC3 (0.54) | ALDH1A1ATMKDM4EGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254124-B1 | DIPEPTIDE NITRILE CATHEPSIN K INHIBITORS | NOVARTIS AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-20070191392-A1 | DIPEPTIDE NITRILE CATHESPIN K INHIBITORS | NORVARTIS AG (CH) | 2007-08-16 | — | — | US | disclosed |
| US-20050267129-A1 | Dipeptide nitrile cathepsin K inhibitors | NORVARTIS AG (CH) | 2005-12-01 | — | — | US | disclosed |
| US-6642239-B2 | Compounds such as N-(1-(cyanomethylcarbamoyl)cyclohexyl)-4-(piperazin-1-yl)-benzamide | NOVARTIS AG (CH) | 2003-11-04 | — | — | US | disclosed |
| US-20030203919-A1 | Dipeptide nitrile cathepsin K inhibitors | MISSBACH MARTIN (CH) | 2003-10-30 | — | — | US | disclosed |
| EP-1254124-A1 | DIPEPTIDE NITRILE CATHPSIN K INHIBITORS | Novartis AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| US-20010016207-A1 | Dipeptide nitrile cathepsin K inhibitors | NOVARTIS AG (CH) | 2001-08-23 | — | — | US | disclosed |
| WO-2001058886-A1 | DIPEPTIDE NITRILE CATHEPSIN K INHIBITORS | NOVARTIS AG (CH) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203919-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSC, CTSS | CHRM1 2713/4885CHRM3 3943/4885SLC18A3 4536/4885 |
| US-20050267129-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSL, CTSV | CHRM1 860/4885CHRM3 2370/4885SLC18A3 3912/4885 |
| US-20010016207-A1 | Dipeptide nitrile cathepsin K inhibitors | CTSK, CTSC, CTSS | CHRM1 2713/4885CHRM3 3943/4885SLC18A3 4536/4885 |
| US-20070191392-A1 | DIPEPTIDE NITRILE CATHESPIN K INHIBITORS | CTSL, CTSK, CTSC | CHRM1 740/4885CHRM3 1818/4885SLC18A3 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.